IMNM (Immunome) Other Current Liabilities: $6.24 Mil (As of Mar. 2026)


IMNM Immunome Inc IMNM
44 GF Score
Price $23.35
GF Value $2.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Immunome Other Current Liabilities?

Immunome IMNM -3.39% 44 Other Current Liabilities is $6.24 Mil as of Mar. 2026. GuruFocus rates IMNM with a GF Score™ of 44/100 and a GF Value™ of $2.00 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Immunome's other current liabilities for the quarter that ended in Mar. 2026 was $6.24 Mil.

Immunome's quarterly other current liabilities increased from Sep. 2025 ($8.91 Mil) to Dec. 2025 ($15.15 Mil) but then declined from Dec. 2025 ($15.15 Mil) to Mar. 2026 ($6.24 Mil).

Immunome's annual other current liabilities increased from Dec. 2023 ($4.90 Mil) to Dec. 2024 ($13.84 Mil) and increased from Dec. 2024 ($13.84 Mil) to Dec. 2025 ($15.15 Mil).

Immunome Other Current Liabilities Related Terms

Immunome Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Immunome's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunome Other Current Liabilities Chart

Immunome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 1.25 1.96 4.90 13.84 15.15

Immunome Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.20 6.82 8.91 15.15 6.24
IMNM
44GF Score
Immunome Inc IMNM
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunome Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $6.24 Mil mean?
Immunome (IMNM) has a Other Current Liabilities of $6.24 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Immunome.
Is Immunome's Other Current Liabilities too high?
Immunome's current Other Current Liabilities is $6.24 Mil. Overall, Immunome has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunome's Other Current Liabilities compare to AGIO and ABCL?
Immunome's Other Current Liabilities of $6.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Immunome. Immunome's current Other Current Liabilities is $6.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunome stock overvalued right now?
Based on GuruFocus' analysis, Immunome (IMNM) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.00, compared to a current price of $23.35 — trading 1067.5% above its estimated fair value. The current Other Current Liabilities is $6.24 Mil. Immunome's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Immunome (IMNM), the current Other Current Liabilities is $6.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunome (IMNM) Overvalued in 2026?

Based on GuruFocus' analysis, Immunome stock appears to be overvalued. The current stock price of $23.35 is trading 1067.5% above its estimated GF Value™ of $2.00. GuruFocus considers Immunome to be Significantly Overvalued.

Key valuation signals for IMNM:

  • Other Current Liabilities: $6.24 Mil
  • GF Value™: $2.00 vs. price of $23.35 (1067.5% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunome Business Description

Address 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score

Get the complete analysis for IMNM

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.35
Price
$2.00
GF Value